Evolocumab’s Potential in Primary Prevention for Diabetic Patients
A new prespecified subgroup analysis from the multinational VESALIUS-CV randomized clinical trial, published in JAMA, investigates whether the PCSK9 inhibitor evolocumab can prevent a first major cardiovascular event in adult patients with diabetes but without known significant atherosclerosis. This research addresses a critical gap in primary prevention strategies, focusing on a high-risk patient population where traditional risk management may be insufficient. The findings could influence future guidelines on lipid-lowering therapy and cardiovascular risk stratification in gastroenterology and hepatology, particularly for patients with diabetes who also have comorbid conditions like non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), where cardiovascular disease is a leading cause of mortality.
Study Significance: For gastroenterologists and hepatologists managing patients with complex metabolic syndromes, this trial’s outcome is highly relevant. It directly informs the integrated care of patients with diabetes and liver conditions, where cardiovascular risk mitigation is paramount. A positive result could shift clinical practice towards earlier, more aggressive use of PCSK9 inhibitors in this subset, impacting treatment algorithms and interdisciplinary management between digestive health and cardiology specialists.
Source →Stay curious. Stay informed — with Science Briefing.
This is a one time Briefing, Upgrade to continue.
Upgrade and get 50% Off — Coupon: ERWMCWYU
